at least 70 years of age and have newly diagnosed acute myeloid leukemia (AML) for whom the
doctor does not recommend the use of standard intensive treatment or the patient has decided
not to receive standard intensive treatment after being fully informed about its benefits
and risks by his/her doctor. The two drug regimens are sapacitabine administered in
alternating cycles with decitabine, or decitabine alone. The purpose of the study is to
learn which drug regimen is more likely to keep AML in check as long as possible.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: email@example.com
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.